NO891787L - Molekylaere lokkemidler og fremgangsmaate for anvendelse derav. - Google Patents

Molekylaere lokkemidler og fremgangsmaate for anvendelse derav.

Info

Publication number
NO891787L
NO891787L NO89891787A NO891787A NO891787L NO 891787 L NO891787 L NO 891787L NO 89891787 A NO89891787 A NO 89891787A NO 891787 A NO891787 A NO 891787A NO 891787 L NO891787 L NO 891787L
Authority
NO
Norway
Prior art keywords
receptor
agent
endogenous
molecular
retained
Prior art date
Application number
NO89891787A
Other languages
English (en)
Norwegian (no)
Other versions
NO891787D0 (no
Inventor
Jonathan M Gershoni
Original Assignee
Jonathan M Gershoni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jonathan M Gershoni filed Critical Jonathan M Gershoni
Publication of NO891787D0 publication Critical patent/NO891787D0/no
Publication of NO891787L publication Critical patent/NO891787L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70514CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Paper (AREA)
  • Battery Electrode And Active Subsutance (AREA)
NO89891787A 1987-08-30 1989-04-28 Molekylaere lokkemidler og fremgangsmaate for anvendelse derav. NO891787L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL8368787A IL83687A (en) 1987-08-30 1987-08-30 Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
PCT/US1988/002991 WO1989001779A1 (en) 1987-08-30 1988-08-30 Molecular decoyants and methods of use thereof

Publications (2)

Publication Number Publication Date
NO891787D0 NO891787D0 (no) 1989-04-28
NO891787L true NO891787L (no) 1989-06-06

Family

ID=11058121

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89891787A NO891787L (no) 1987-08-30 1989-04-28 Molekylaere lokkemidler og fremgangsmaate for anvendelse derav.

Country Status (12)

Country Link
US (1) US5770572A (https=)
EP (1) EP0329778B1 (https=)
JP (1) JP2791074B2 (https=)
AT (1) ATE123224T1 (https=)
AU (1) AU2383988A (https=)
CA (1) CA1336489C (https=)
DE (1) DE3853910T2 (https=)
DK (1) DK175596B1 (https=)
FI (1) FI100169B (https=)
IL (1) IL83687A (https=)
NO (1) NO891787L (https=)
WO (1) WO1989001779A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02501192A (ja) * 1987-09-04 1990-04-26 バイオジェン インコーポレイテッド 可溶性t4蛋白を製造するためのdna配列、組換dna分子および方法
US5132402A (en) * 1987-11-25 1992-07-21 Agency Of Industrial Science And Technology Adsorbent, method for production thereof, and method for use thereof
EP0318240A3 (en) * 1987-11-25 1990-08-16 AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY MINISTRY OF INTERNATIONAL TRADE & INDUSTRY Peptide, adsorbent, method for production thereof, and method for use thereof
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
ITRM20010563A1 (it) * 2001-09-14 2003-03-14 Univ Siena Peptidi antigenici multipli come antidoti nell'intossicazione da veleno di serpente.
US8535672B2 (en) * 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
RU2005102604A (ru) * 2002-07-03 2005-09-10 Перикор Сайенс, Инк. (Us) Композиция гиалуроновой кислоты и способы применения
JP4495776B1 (ja) * 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015153647A1 (en) * 2014-03-31 2015-10-08 Mice With Horns, Llc Method of preventing or reducing virus transmission in animals
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570278B1 (fr) * 1984-09-14 1987-02-13 Pasteur Institut Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
DE3751751T2 (de) * 1986-08-21 1996-10-17 Univ Columbia Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids

Also Published As

Publication number Publication date
JP2791074B2 (ja) 1998-08-27
DK175596B1 (da) 2004-12-13
EP0329778B1 (en) 1995-05-31
IL83687A0 (https=) 1988-01-31
FI100169B (fi) 1997-10-15
US5770572A (en) 1998-06-23
IL83687A (en) 1995-03-30
WO1989001779A1 (en) 1989-03-09
EP0329778A1 (en) 1989-08-30
JPH02502538A (ja) 1990-08-16
FI892005A0 (fi) 1989-04-27
CA1336489C (en) 1995-08-01
DK211989D0 (da) 1989-05-01
DE3853910D1 (de) 1995-07-06
AU2383988A (en) 1989-03-31
EP0329778A4 (en) 1990-12-27
FI892005L (fi) 1989-04-27
DK211989A (da) 1989-06-28
ATE123224T1 (de) 1995-06-15
DE3853910T2 (de) 1995-10-12
NO891787D0 (no) 1989-04-28

Similar Documents

Publication Publication Date Title
NO891787L (no) Molekylaere lokkemidler og fremgangsmaate for anvendelse derav.
ATE150616T1 (de) Verabreichungszusammensetzungen für unkrautvertilgungsmittel sowie verfahren zur regelung der pflanzenbevölkerung in wässriger und sumpfähnlicher umgebung
NO820433L (no) Legemiddelfrigivende preparat
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
ES2124702T3 (es) Usos terapeuticos de compuestos que se unen a actina.
BR0008188A (pt) Inibidores de fator de diferenciação de crescimento e usos para os mesmos
NO902446D0 (no) Dyrefor og fremgangsmaater for deres fremstilling.
YU87090A (sh) Postupak za prečišćavanje himopapaina
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
DE3877547D1 (de) Basisches protein phospholipase a2 aus dem gift der schlangen aus der familie der elapiden, deren aminosaeuresequenz, derivate und fragmente dieses proteins, verfahren um es zu erhalten, therapeutische kompositionen und diagnosemittel, alle dieses protein enthaltend und/oder dessen derivate und/oder dessen fragmente.
DK0517986T3 (da) Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DK345889D0 (da) Anvendelse af 5-ht-3-receptorantagonist
DK0544760T3 (da) Farmaceutiske præparater indeholdende 5-difluormethoxy-2- (3,4-dimethoxy-2-pyridyl)methylsulfinyl benzimidazol og at anti-helicobactermiddel til behandling af gastrointestinale lidelser
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
BR9808424A (pt) Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto.
Hill Role of Ca2+ in excitation–contraction coupling in echinoderm muscle: comparison with role in other tissues
Sandberg et al. Inflammatogenic and adjuvant properties of HEMA in mice
DE69007374D1 (de) Injektionssystem für die Behandlung von Zellen.
NO881111D0 (no) Fremgangsmaate til isolering av basalmembranproteiner fra menneskelige og dyriske vev.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DK467885D0 (da) Middel til behandling og forebyggelse af diarre hos dyr og mennesker,og fremgangsmaade til fremstilling af et saadant middel
DK31781A (da) N,n-dielkyl-o-(pyrazol-5-yl)-carbaminsyreestere fremgangsmaade til deres fremstilling og deres anvendelse som insecticider
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme
Terasaki et al. ANTIBODY RESPONSE TO HOMOGRAFTS. IV. TIME OF APPEARANCE OF LYM-PHOAGGLUTININS IN PARTIALLY TOLERANT ANIMALS